tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Halozyme Therapeutics Inc

HALO
Add to Watchlist
82.540USD
-0.760-0.91%
Close 07-31 16:00（ET）Quotes delayed by 15 min
9.79BMarket Cap
27.92P/E TTM

Halozyme Therapeutics Inc

82.540
-0.760-0.91%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

HALO Financials

See Halozyme Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Halozyme Therapeutics Inc Earnings Date

Latest Release
Aug 6, 2026
EPS / Forecast
--/1.84
Revenue / Forecast
--/407.49M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
1.40B
37.55%
EPS(YoY)
2.64
-24.48%
Analyst Rating
BUY
2026/07/31
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
32.51%1.27
-211.03%-1.20
38.40%1.49
85.55%1.36
58.37%0.96
63.78%1.08
74.17%1.08
29.26%0.73
106.27%0.61
55.15%0.66
--0.62
--0.57
--0.29
--0.43
----
----
----
----
----
----
Revenue
42.23%376.71M
51.60%451.77M
22.12%354.26M
40.79%325.72M
35.22%264.86M
29.55%298.01M
34.28%290.08M
4.67%231.35M
20.81%195.88M
26.75%230.04M
3.38%216.03M
45.07%221.04M
38.25%162.14M
77.93%181.50M
80.42%208.98M
11.66%152.37M
31.74%117.28M
-16.19%102.00M
77.34%115.83M
147.11%136.46M
Net Profit
27.06%150.05M
-203.34%-141.59M
27.89%175.22M
77.12%165.16M
53.72%118.09M
60.46%137.01M
67.42%137.01M
24.74%93.25M
93.92%76.82M
47.98%85.39M
32.78%81.84M
229.53%74.75M
-34.09%39.62M
-13.58%57.70M
-71.54%61.63M
-75.20%22.68M
115.48%60.11M
-8.74%66.77M
498.19%216.59M
254.25%91.46M
Net Margin
-10.67%39.83%
-168.17%-31.34%
4.72%49.46%
25.81%50.71%
13.69%44.59%
23.86%45.98%
24.68%47.23%
19.17%40.30%
60.52%39.22%
16.75%37.12%
--37.88%
--33.82%
--24.43%
--31.79%
----
----
----
----
----
----
Gross Margin
-5.18%71.13%
-3.18%77.39%
3.32%79.39%
6.80%80.31%
-1.90%75.02%
14.93%79.93%
15.78%76.84%
8.55%75.20%
13.61%76.47%
-6.38%69.54%
--66.36%
--69.28%
--67.31%
--74.28%
----
----
----
----
----
----
Debt to assets ratio
16.92%80.24%
16.27%84.85%
-4.23%68.01%
-3.69%73.47%
-15.80%68.63%
-15.64%72.97%
-10.25%71.02%
-7.67%76.29%
-7.31%81.50%
5.76%86.50%
--79.13%
--82.63%
--87.93%
--81.79%
----
----
----
----
----
----
Income Statement
Revenue
42.23%376.71M
51.60%451.77M
22.12%354.26M
40.79%325.72M
35.22%264.86M
29.55%298.01M
34.28%290.08M
4.67%231.35M
20.81%195.88M
26.75%230.04M
3.38%216.03M
45.07%221.04M
38.25%162.14M
77.93%181.50M
80.42%208.98M
11.66%152.37M
31.74%117.28M
-16.19%102.00M
77.34%115.83M
147.11%136.46M
Operating profit
30.37%184.52M
44.95%254.40M
33.53%217.92M
72.68%202.44M
48.14%141.53M
73.70%175.50M
79.77%163.20M
24.11%117.23M
77.58%95.54M
33.10%101.03M
8.47%90.78M
79.37%94.46M
-30.28%53.80M
34.27%75.91M
10.72%83.69M
-43.40%52.66M
52.10%77.17M
-27.17%56.53M
87.56%75.59M
214.83%93.05M
Net Profit
27.06%150.05M
-203.34%-141.59M
27.89%175.22M
77.12%165.16M
53.72%118.09M
60.46%137.01M
67.42%137.01M
24.74%93.25M
93.92%76.82M
47.98%85.39M
32.78%81.84M
229.53%74.75M
-34.09%39.62M
-13.58%57.70M
-71.54%61.63M
-75.20%22.68M
115.48%60.11M
-8.74%66.77M
498.19%216.59M
254.25%91.46M
Balance Sheet
Current assets
-20.52%1.00B
-23.97%825.21M
17.90%1.33B
13.65%1.12B
44.47%1.26B
45.41%1.09B
28.21%1.13B
29.00%987.80M
42.04%873.58M
1.00%746.42M
34.57%879.01M
41.30%765.75M
-37.79%615.02M
-20.22%739.01M
-35.79%653.20M
-45.79%541.94M
4.99%988.69M
66.97%926.29M
103.91%1.02B
99.81%999.75M
Total current liabilities
141.53%363.21M
27.31%177.09M
669.40%837.23M
0.69%134.28M
14.24%150.38M
23.65%139.10M
-5.53%108.81M
14.58%133.36M
43.21%131.64M
-13.99%112.49M
5.30%115.19M
-41.66%116.39M
-17.70%91.92M
11.65%130.79M
-3.33%109.38M
74.63%199.51M
3.98%111.69M
-72.20%117.15M
319.46%113.15M
338.20%114.25M
Total assets
21.68%2.67B
22.38%2.53B
4.87%2.22B
4.29%2.05B
19.28%2.20B
19.05%2.06B
11.91%2.12B
8.78%1.97B
8.36%1.84B
-5.88%1.73B
1.51%1.89B
1.63%1.81B
46.22%1.70B
66.74%1.84B
57.29%1.86B
73.65%1.78B
20.24%1.16B
90.44%1.10B
126.21%1.19B
94.66%1.03B
Total liabilities
43.10%2.45B
45.71%2.48B
3.12%1.72B
2.45%1.72B
3.04%1.71B
3.04%1.70B
1.33%1.67B
1.24%1.68B
1.84%1.66B
-1.33%1.65B
-7.02%1.64B
11.50%1.66B
81.11%1.63B
84.22%1.67B
95.58%1.77B
64.24%1.49B
0.33%901.99M
111.59%907.48M
112.63%903.75M
115.01%906.12M
Total equity
-54.46%219.64M
-86.58%48.81M
11.31%503.92M
14.97%332.75M
171.23%482.27M
334.11%363.82M
81.68%452.70M
91.63%289.42M
170.02%177.81M
-50.64%83.81M
156.91%249.18M
-48.48%151.03M
-74.70%65.85M
-13.79%169.80M
-65.57%96.99M
144.82%293.17M
285.02%260.26M
30.39%196.95M
184.55%281.67M
13.42%119.75M
Cash Flow Statement
Net operating income
16.77%180.08M
22.73%219.03M
54.80%178.60M
78.71%99.71M
19.16%154.22M
74.36%178.47M
-12.87%115.38M
-16.53%55.79M
48.83%129.43M
24.14%102.35M
90.15%132.41M
66.17%66.84M
81.94%86.96M
-0.08%82.45M
-42.80%69.64M
9.04%40.23M
-18.01%47.80M
62.05%82.52M
1900.97%121.74M
1019.88%36.89M
Net investment
96.82%-2.88M
-2616.24%-741.79M
220.38%201.61M
301.69%84.79M
-9.36%-90.42M
455.57%29.48M
-100.70%-167.48M
-176.44%-42.04M
-37.43%-82.68M
-374.86%-8.29M
-8178.77%-83.45M
112.64%54.99M
-22.02%-60.16M
99.42%-1.75M
94.05%-1.01M
-874.87%-434.95M
-8.96%-49.30M
-612.43%-299.47M
43.67%-16.95M
-474.96%-44.62M
Net financing
51.43%-1.61M
197.20%239.51M
-220.69%-22.40M
-3252.98%-298.97M
-579.14%-3.32M
1.40%-246.41M
352.60%18.56M
287.65%9.48M
99.70%-489.00K
-4048.81%-249.92M
133.07%4.10M
-99.33%2.45M
-26480.45%-164.61M
104.06%6.33M
79.36%-12.40M
921.81%367.82M
-99.82%624.00K
-469.40%-156.01M
-36.97%-60.07M
-429.27%-44.76M

FAQs

What is the total revenue of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its total revenue reached 1.40B, with a year-on-year change of 1.02B.

What are the current assets of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its current assets were 825.21M, with a year-on-year change of -23.97.

What are the total assets of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its total assets of Halozyme Therapeutics Inc were 2.53B, with a year-on-year change of 22.38.

What are the total liabilities of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its total liabilities of Halozyme Therapeutics Inc were 2.48B, with a year-on-year change of 45.71.

What is the total equity of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its total equity of Halozyme Therapeutics Inc was 48.81M, with a year-on-year change of -86.58.

What is the net operating income of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its net operating income of Halozyme Therapeutics Inc was 816.29M, with a year-on-year change of 48.02.

What is the net investment of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its net investment of Halozyme Therapeutics Inc was -545.81M, with a year-on-year change of -107.75.

What is the net financing of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its net financing of Halozyme Therapeutics Inc was -85.17M, with a year-on-year change of 61.08.

What is the Earnings Per Share (EPS) of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 2.64, with a year-on-year change of -24.48.

What is the net income of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its net income was 316.89M, with a year-on-year change of -28.64.

What is the net margin of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its net profit margin was 22.69, with a year-on-year change of -48.12.

What is the gross margin of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its gross margin was 78.13, with a year-on-year change of 1.07.

What is the debt-to-asset ratio of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its debt-to-asset ratio was 84.85, with a year-on-year change of 16.27.

What is the Return on Equity (ROE) of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was 153.59, with a year-on-year change of -22.59.

What is the Return on Assets (ROA) of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was 13.81, with a year-on-year change of -40.96.

What is the operating profit of Halozyme Therapeutics Inc?

According to Halozyme Therapeutics Inc's FY2025 earnings report, its operating profit was 816.29M, with a year-on-year change of 48.02.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy